Диссертация (1140892), страница 22
Текст из файла (страница 22)
338, № 3. ‒ C. 1307-15.73. Pardanani A., Baek J. Y., Li C. Y., Butterfield J. H., Tefferi A. Systemic mast cell disease withoutassociated hematologic disorder: a combined retrospective and prospective study // Mayo ClinProc. ‒ 2002. ‒ T. 77, № 11. ‒ C. 1169-75.74. Merz H., Kaehler C., Hoefig K. P., Branke B., Uckert W., Nadrowitz R., Cerny-Reiterer S.,Herrmann H., Feller A. C., Valent P. Interleukin-9 (IL-9) and NPM-ALK each generate mastcell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice //Oncotarget. ‒ 2010.
‒ T. 1, № 2. ‒ C. 104-19.75. Reber L. L., Sibilano R., Mukai K., Galli S. J. Potential effector and immunoregulatory functionsof mast cells in mucosal immunity // Mucosal Immunol. ‒ 2015. ‒ T. 8, № 3. ‒ C. 444-63.76. Bai C. G., Hou X. W., Wang F., Qiu C., Zhu Y., Huang L., Zhao J., Xu J. J., Ma D. L. Stem cellfactor-mediated wild-type KIT receptor activation is critical for gastrointestinal stromal tumorcell growth // World J Gastroenterol. ‒ 2012. ‒ T. 18, № 23.
‒ C. 2929-37.77. Cruse G., Metcalfe D. D., Olivera A. Functional deregulation of KIT: link to mast cell proliferativediseases and other neoplasms // Immunol Allergy Clin North Am. ‒ 2014. ‒ T. 34, № 2. ‒ C.219-37.78. Besmer P., Manova K., Duttlinger R., Huang E. J., Packer A., Gyssler C., Bachvarova R. F. Thekit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gametogenesis andmelanogenesis // Dev Suppl.
‒ 1993. ‒ C. 125-37.79. Lennartsson J., Ronnstrand L. The stem cell factor receptor/c-Kit as a drug target in cancer // CurrCancer Drug Targets. ‒ 2006. ‒ T. 6, № 1. ‒ C. 65-75.80. Keller J. R., Ortiz M., Ruscetti F. W. Steel factor (c-kit ligand) promotes the survival ofhematopoietic stem/progenitor cells in the absence of cell division // Blood. ‒ 1995. ‒ T.
86, №5. ‒ C. 1757-64.81. Yarden Y., Kuang W. J., Yang-Feng T., Coussens L., Munemitsu S., Dull T. J., Chen E.,Schlessinger J., Francke U., Ullrich A. Human proto-oncogene c-kit: a new cell surfacereceptor tyrosine kinase for an unidentified ligand // EMBO J. ‒ 1987. ‒ T. 6, № 11. ‒ C.3341-51.13482. Lyman S. D., Jacobsen S. E. c-kit ligand and Flt3 ligand: stem/progenitor cell factors withoverlapping yet distinct activities // Blood. ‒ 1998.
‒ T. 91, № 4. ‒ C. 1101-34.83. Hjertson M., Sundstrom C., Lyman S. D., Nilsson K., Nilsson G. Stem cell factor, but not flt3ligand, induces differentiation and activation of human mast cells // Exp Hematol. ‒ 1996. ‒ T.24, № 6. ‒ C. 748-54.84. Blechman J. M., Lev S., Barg J., Eisenstein M., Vaks B., Vogel Z., Givol D., Yarden Y. The fourthimmunoglobulin domain of the stem cell factor receptor couples ligand binding to signaltransduction // Cell. ‒ 1995.
‒ T. 80, № 1. ‒ C. 103-13.85. Lemmon M. A., Pinchasi D., Zhou M., Lax I., Schlessinger J. Kit receptor dimerization is drivenby bivalent binding of stem cell factor // J Biol Chem. ‒ 1997. ‒ T. 272, № 10. ‒ C. 6311-7.86. Roskoski R., Jr. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor // BiochemBiophys Res Commun. ‒ 2005. ‒ T. 337, № 1. ‒ C. 1-13.87.
Foster R., Griffith R., Ferrao P., Ashman L. Molecular basis of the constitutive activity and STI571resistance of Asp816Val mutant KIT receptor tyrosine kinase // J Mol Graph Model. ‒ 2004. ‒T. 23, № 2. ‒ C. 139-52.88. Mol C. D., Dougan D. R., Schneider T. R., Skene R. J., Kraus M. L., Scheibe D. N., Snell G. P.,Zou H., Sang B. C., Wilson K. P. Structural basis for the autoinhibition and STI-571 inhibitionof c-Kit tyrosine kinase // J Biol Chem.
‒ 2004. ‒ T. 279, № 30. ‒ C. 31655-63.89. Arock M., Akin C., Hermine O., Valent P. Current treatment options in patients with mastocytosis:status in 2015 and future perspectives // Eur J Haematol. ‒ 2015. ‒ T. 94, № 6. ‒ C. 474-90.90. Jawhar M., Schwaab J., Schnittger S., Meggendorfer M., Pfirrmann M., Sotlar K., Horny H. P.,Metzgeroth G., Kluger S., Naumann N., Haferlach C., Haferlach T., Valent P., Hofmann W.K., Fabarius A., Cross N.
C., Reiter A. Additional mutations in SRSF2, ASXL1 and/orRUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemicmastocytosis // Leukemia. ‒ 2016. ‒ T. 30, № 1. ‒ C. 136-43.91. Jawhar M., Schwaab J., Schnittger S., Sotlar K., Horny H. P., Metzgeroth G., Muller N., SchneiderS., Naumann N., Walz C., Haferlach T., Valent P., Hofmann W. K., Cross N. C., Fabarius A.,Reiter A. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemicmastocytosis identifies KIT D816V as a distinct and late event // Leukemia.
‒ 2015. ‒ T. 29,№ 5. ‒ C. 1115-22.92. Hashimoto K., Tsujimura T., Moriyama Y., Yamatodani A., Kimura M., Tohya K., Morimoto M.,Kitayama H., Kanakura Y., Kitamura Y. Transforming and differentiation-inducing potentialof constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mastcell line // Am J Pathol. ‒ 1996. ‒ T. 148, № 1. ‒ C. 189-200.13593. Tsujimura T., Hashimoto K., Kitayama H., Ikeda H., Sugahara H., Matsumura I., Kaisho T.,Terada N., Kitamura Y., Kanakura Y. Activating mutation in the catalytic domain of c-kitelicits hematopoietic transformation by receptor self-association not at the ligand-induceddimerization site // Blood.
‒ 1999. ‒ T. 93, № 4. ‒ C. 1319-29.94. Saleh R., Wedeh G., Herrmann H., Bibi S., Cerny-Reiterer S., Sadovnik I., Blatt K.,Hadzijusufovic E., Jeanningros S., Blanc C., Legarff-Tavernier M., Chapiro E., Nguyen-KhacF., Subra F., Bonnemye P., Dubreuil P., Desplat V., Merle-Beral H., Willmann M., Rulicke T.,Valent P., Arock M.
A new human mast cell line expressing a functional IgE receptor convertsto tumorigenic growth by KIT D816V transfection // Blood. ‒ 2014. ‒ T. 124, № 1. ‒ C. 11120.95. Cardet J. C., Akin C., Lee M. J. Mastocytosis: update on pharmacotherapy and future directions //Expert Opin Pharmacother.
‒ 2013. ‒ T. 14, № 15. ‒ C. 2033-45.96. Haenisch B., Nothen M. M., Molderings G. J. Systemic mast cell activation disease: the role ofmolecular genetic alterations in pathogenesis, heritability and diagnostics // Immunology. ‒2012. ‒ T. 137, № 3. ‒ C. 197-205.97. Longley B. J., Jr., Metcalfe D. D., Tharp M., Wang X., Tyrrell L., Lu S. Z., Heitjan D., Ma Y.Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinicalforms of human mastocytosis // Proc Natl Acad Sci U S A. ‒ 1999.
‒ T. 96, № 4. ‒ C. 1609-14.98. Sotlar K., Escribano L., Landt O., Mohrle S., Herrero S., Torrelo A., Lass U., Horny H. P.,Bultmann B. One-step detection of c-kit point mutations using peptide nucleic acid-mediatedpolymerase chain reaction clamping and hybridization probes // Am J Pathol. ‒ 2003. ‒ T. 162,№ 3. ‒ C. 737-46.99. Pullarkat V.
A., Bueso-Ramos C., Lai R., Kroft S., Wilson C. S., Pullarkat S. T., Bu X., Thein M.,Lee M., Brynes R. K. Systemic mastocytosis with associated clonal hematological non-mastcell lineage disease: analysis of clinicopathologic features and activating c-kit mutations // AmJ Hematol. ‒ 2003. ‒ T. 73, № 1. ‒ C. 12-7.100. Nagai S., Ichikawa M., Takahashi T., Sato H., Yokota H., Oshima K., Izutsu K., Hangaishi A.,Kanda Y., Motokura T., Chiba S., Yatomi Y., Kurokawa M. The origin of neoplastic mastcells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia // ExpHematol.
‒ 2007. ‒ T. 35, № 11. ‒ C. 1747-52.101. Ustun C., Corless C. L., Savage N., Fiskus W., Manaloor E., Heinrich M. C., Lewis G.,Ramalingam P., Kepten I., Jillella A., Bhalla K. Chemotherapy and dasatinib induce long-termhematologic and molecular remission in systemic mastocytosis with acute myeloid leukemiawith KIT D816V // Leuk Res. ‒ 2009. ‒ T. 33, № 5. ‒ C. 735-41.136102. Sotlar K., Colak S., Bache A., Berezowska S., Krokowski M., Bultmann B., Valent P., Horny H.P. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseasesassociated with systemic mastocytosis (SM-AHNMD) // J Pathol.
‒ 2010. ‒ T. 220, № 5. ‒ C.586-95.103. Longley B. J., Reguera M. J., Ma Y. Classes of c-KIT activating mutations: proposedmechanisms of action and implications for disease classification and therapy // Leuk Res. ‒2001. ‒ T. 25, № 7. ‒ C. 571-6.104. Zappulla J. P., Dubreuil P., Desbois S., Letard S., Hamouda N. B., Daeron M., Delsol G., ArockM., Liblau R. S. Mastocytosis in mice expressing human Kit receptor with the activatingAsp816Val mutation // J Exp Med.
‒ 2005. ‒ T. 202, № 12. ‒ C. 1635-41.105. Verzijl A., Heide R., Oranje A. P., van Schaik R. H. C-kit Asp-816-Val mutation analysis inpatients with mastocytosis // Dermatology. ‒ 2007. ‒ T. 214, № 1. ‒ C. 15-20.106. Grimwade L. F., Happerfield L., Tristram C., McIntosh G., Rees M., Bench A. J., Boyd E. M.,Hall M., Quinn A., Piggott N., Scorer P., Scott M. A., Erber W.
N. Phospho-STAT5 andphospho-Akt expression in chronic myeloproliferative neoplasms // Br J Haematol. ‒ 2009. ‒T. 147, № 4. ‒ C. 495-506.107. Harir N., Boudot C., Friedbichler K., Sonneck K., Kondo R., Martin-Lanneree S., Kenner L.,Kerenyi M., Yahiaoui S., Gouilleux-Gruart V., Gondry J., Benit L., Dusanter-Fourt I.,Lassoued K., Valent P., Moriggl R., Gouilleux F. Oncogenic Kit controls neoplastic mast cellgrowth through a Stat5/PI3-kinase signaling cascade // Blood.
‒ 2008. ‒ T. 112, № 6. ‒ C.2463-73.108. Bibi S., Arslanhan M. D., Langenfeld F., Jeanningros S., Cerny-Reiterer S., Hadzijusufovic E.,Tchertanov L., Moriggl R., Valent P., Arock M. Co-operating STAT5 and AKT signalingpathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy //Haematologica. ‒ 2014. ‒ T. 99, № 3. ‒ C.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
